Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
about
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Quantification of HER family receptors in breast cancerAdjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumorsCan maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?The Therapeutic Challenge of Targeting HER2 in Endometrial CancerEfficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceHigh HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.Is there any cumulative dose for trastuzumab?P95 HER2 fragments and breast cancer outcome.Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.HER2-positive breast cancer is lost in translation: time for patient-centered research.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Trastuzumab in metastatic breast cancer after complete remission: an expensive commitment for an entire life?Trastuzumab in metastatic breast cancer after complete remission: How long is enough?Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases.
P2860
Q26746081-3CF5A199-E2C0-416D-9D9B-D7DAB20DA678Q27015506-4EFDF219-74DE-4EE1-A198-9308C1CD1DA4Q34010867-F192B14A-F85D-44C9-B874-94F9BCA32C8DQ35176075-7645220F-5746-4A81-AAF8-5E21EADDF3A5Q35699689-1F91D18D-76A7-4C5A-9F46-57A1CEB5D42AQ36064912-0F00C41E-7F6B-4D07-9E79-C65E5D15CD4BQ36250585-18FB3CA8-13D1-4144-9CBA-5503A3343FAAQ37142882-6F6DA53B-E22F-4117-A708-730E56B6C1B5Q37166436-A4D71CDE-6F89-43E3-A8C5-971E97466377Q38218014-D2BF00E1-450A-4925-B6DF-C25B45F7EB28Q38223511-BB53B562-756E-4014-A3A8-5E0807215407Q38289356-5343FEF9-5F5F-431A-A43E-B4D4B8232EF0Q38563592-414A85B1-F5FA-4707-B4CF-37BF454D71F8Q38591976-FF34F68C-9C02-4A60-BE17-415867DDE92CQ38648765-DD709D3B-43F2-466C-B3CE-E1A28CA2BA71Q38661390-12E81B40-2E3B-4231-B325-4BA59E96C27EQ38812867-75910EE7-E613-4072-A6AB-A1B7AC0EF22BQ41932811-85ECD425-423E-47B7-9C1D-970C7E9CCEE0Q53448286-9E005DB8-804B-410F-9050-F20E09AAFEE1Q54957080-BE864BD6-DDAC-4054-8C9A-09C0E14F0B40Q55100041-35EF64B7-3571-478E-8DD7-07F2B9DFFA8D
P2860
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Potential biomarkers of long-t ...... tive metastatic breast cancer.
@en
type
label
Potential biomarkers of long-t ...... tive metastatic breast cancer.
@en
prefLabel
Potential biomarkers of long-t ...... tive metastatic breast cancer.
@en
P2093
P2860
P50
P1433
P1476
Potential biomarkers of long-t ...... tive metastatic breast cancer.
@en
P2093
Caterina Peraldo-Neia
Jeff Sperinde
José Baselga
Maurizio Scaltriti
Michela Donadio
Patricia Galván
Valentina Rossi
P2860
P356
10.1016/J.MOLONC.2013.08.013
P577
2013-09-13T00:00:00Z